TheraJect was founded in June 2002 and
incorporated in August 2002 by Sung-Yun
Kwon, Ph.D. the inventor of TheraJects
technology.
Value Proposition

TheraJect's platform technology is positioned to pursue
and harvest multiple growth opportunities. TheraJect will
focus on research, development, intellectual property
creation and protection, and preliminary pre-clinical study.
TheraJect's strategy is to earn revenue by licensing and
partnering the development of its technology with vaccine,
pharmaceutical, biotechnology, medical device,
cosmeceuticals, manufacturing, and service provider
companies that have the experience and resources to
efficiently manage processes outside of our core
competencies in pre-clinical product development. This
strategy should provide early yet sustainable returns to
TheraJect's shareholders.
Financial Projections

TheraJect has raised seed funding through Korean and US
investors. These funds with NIH government grant and
Gates Foundation have supported operations since June
2002.  TheraJect has not yet made revenue projections, but
believes the potential to be significant.